Market Newsdesk

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35^th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform

Preclinical findings demonstrate potent antitumor activity, persistence and low toxicity profile of ATA3271, supporting further clinical investigation

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ATA3271, a next-generation, off-the-shelf, allogeneic EBV CAR T-cell therapy targeting mesothelin designed for the treatment of solid tumors. These data are being featured in a poster presentation at the 35^th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020), November 11-14, 2020.

“We have made meaningful progress advancing IND-enabling studies for ATA3271, an allogeneic mesothelin CAR T, which leverages our differentiated EBV T-cell platform and utilizes the PD1DNR and 1XX technologies to improve efficacy, persistence, and durability of response. Such innovative CAR T design addresses key hurdles for realizing the potential for CAR T therapies in solid tumor settings,” said Jakob Dupont, Global Head of Research and Development at Atara. “Mesothelin, an antigen associated with aggressive solid tumors, is a promising target for tumor-specific therapy and combined with our EBV T-cell platform and the PD1DNR and 1XX technologies has led to the potent preclinical antitumor activity of ATA3271 that functionally persists after multiple tumor cell challenges.”

Results presented at SITC detail findings from in vitro and in vivo evaluation of ATA3271. Specifically, in vitro functional studies show potent antitumor activity of ATA3271 against mesothelin-expressing cell lines, with potency maintained in the presence of high tumor PD-L1 expression. These data support the design of ATA3271, which expresses a dominant negative version of PD-1 receptor, to maintain function in the presence of suppressive checkpoint ligands commonly associated with solid tumor microenvironments. In addition, results further support the combined functional design of ATA3271’s 1XX costimulatory domain technology in maintaining memory phenotype while limiting cell exhaustion in the context of repeated tumor cell challenges.

Furthermore, ATA3271 retains reduced allocytotoxic function against HLA mismatched targets, a characteristic that is associated with Atara’s allogeneic EBV T-cell platform that leverages enrichment of endogenous EBV-TCR function to decrease clinical risks for GvHD. We also believe that our allogeneic EBV CAR T-cell platform may prevent cellular exhaustion and augment in vivo expansion.

In vivo, ATA3271 exhibited potent antitumor activity and significant survival benefit in mice implanted with MGM-PDL1 cells that highly express both mesothelin as well as PD-L1. This in vivo potency was demonstrated without evident toxicities. All mice treated with ATA3271 (n=10) survived through the study duration, while control mice (n=10) all died within a median duration of 25 days (15- to 35-day survival range), post tumor implantation. Evidence in six of ten mice also showed that ATA3271 persisted in vivo by day 51. Ex vivo analysis of a subset of these persistent cell populations (n=4) demonstrated maintenance of phenotypic memory markers over the duration of the in vivo activity.

Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, ovarian cancer, pancreatic cancer and non-small cell lung cancer and is an attractive target for immune-based therapies. Both in vitro and in vivo results for ATA3271 suggest that allogeneic mesothelin-CAR-engineered EBV T cells are a promising approach for the treatment of mesothelin-positive cancers.

“The results presented today further support the continued development of our allogeneic mesothelin-targeted next-generation CAR T program,” said AJ Joshi, M.D., Senior Vice President and Chief Medical Officer at Atara. “We look forward to building upon these foundational preclinical studies to advance ATA3271 in the clinic with the goal of bringing a potentially transformative therapeutic option to treat aggressive solid tumors including mesothelioma.”

Atara’s next generation CAR T immunotherapy franchise for mesothelin also includes autologous ATA2271. The U.S. Food and Drug Administration (FDA) recently accepted an Investigational New Drug (IND) application to initiate a Phase 1 clinical study of ATA2271 for the treatment of advanced mesothelioma.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel^® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: preclinical results and data from the IND-enabling studies for ATA3271; the timing and progress of ATA3271 and ATA2271, and Atara’s ability to successfully advance the development of its CAR T programs. Because such statements deal with future events and are based on Atara Biotherapeutics’ current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara’s cash resources and need for additional capital; and other risks and uncertainties affecting Atara’s and its development programs, including those discussed in Atara Biotherapeutics’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005385/en/

INVESTOR & MEDIA:

Media

Kerry Beth Daly

Head, Corporate Communications

Atara Biotherapeutics

516-982-9328

[email protected]

Investors

Eric Hyllengren

Vice President, Investor Relations & Finance

Atara Biotherapeutics

805-395-9669

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

bebe stores, inc. Announces Quarterly Cash Dividend

Board declares quarterly cash dividend of $0.06 per share

SAN FRANCISCO–(BUSINESS WIRE)–
bebe stores, inc. (OTCQB:BEBE) (the “Company”) today announced that its Board of Directors declared a quarterly cash dividend of $0.06 per share of the Company’s common stock payable December 10, 2020, to shareholders of record as of November 24, 2020. The dividend is primarily based on the cash flow driven by licensing income from the bebe and Brookstone brands through the Company’s ownership interests in the BB Brand Holdings LLC and BKST Brand Management LLC joint ventures, respectively.

About bebe stores, inc.

bebe is a global specialty licensor of women’s apparel and accessories that distributes bebe branded products worldwide through its licensees in approximately 100 international stores and www.bebe.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005357/en/

bebe stores, inc.

Mandy Lindly

[email protected]

(415) 251-3355

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Fashion Retail

MEDIA:

Logo

The Peck Company Holdings Reports Third Quarter 2020 Results

Backlog Increased to Company Record $56 Million

SOUTH BURLINGTON, Vt.–(BUSINESS WIRE)–
The Peck Company Holdings, Inc. (NASDAQ: PECK) (the “Company” or “Peck”), a leading commercial solar engineering, procurement and construction (EPC) company, today announced the Company’s financial results for the third quarter ended September 30, 2020 (“Q3 2020”).

Key Highlights for Q3 2020

• Backlog increased to $56 million, from $16 million a year earlier
• Awarded $7.256 million contract for 5.3MW project in Rhode Island
• Awarded $2.365 million contract for 6.8MW project in Maine
• Awarded $7.641 million portfolio for 10.5MW of projects in Vermont
• Announced proposed acquisition of Sunworks
• Recognized as a top solar contractor for 2020, presented by Solar Power World

Management Commentary

The Peck Company Holdings Chairman of the Board and Chief Executive Officer, Jeffrey Peck, commented, “While we did resume and commence all projects previously impacted by the COVID-19 pandemic, Vermont’s State of Emergency was extended to November 15, 2020 resulting in more unpredictability. We continue to provide service and maintenance in support of critical infrastructure including utilities and telecommunications.”

Mr. Peck, continued, “With no projects cancelled, but many pushed out, our backlog has swelled to $56 million. Our record demand includes projects in our home state of Vermont as well as our regional expansion into Maine and Rhode Island. Our first project in Rhode Island is a milestone we are very excited about in helping with their renewable energy goals. We look forward to our continued expansion into Rhode Island, Maine, other states in the northeast and coast to coast. We expect to realize nearly all of the backlog within the next 12 months and anticipate that revenue growth will return and accelerate as we return to some normalcy post the COVID-19 pandemic.”

Mr. Peck, concluded, “Our previously announced proposed acquisition of Sunworks remains on track to close by the end of the year. We are excited for the potential of the two companies becoming one in creating an industry leading solar EPC with a national presence.”

Financial Results for the Three Months Ended September 30, 2020

Revenue for the three months ended September 30, 2020 was $5.0 million, a decrease of $6.8 million, or 58%, compared to $11.7 million for the three months ended September 30, 2019. Due to the State of Emergency declared by the State of Vermont, the Company was unable to complete or begin several projects due to the current COVID-19 pandemic.

Backlog at September 30, 2020 was $56 million, compared to the corresponding period in 2019 of $16 million. The Company expects to realize nearly all of the backlog within the next 12 months.

Gross profit for the three months ended September 30, 2020 was $0.2 million, a decrease of $1.2 million, or 84%, compared to $1.4 million for the three months ended September 30, 2019. The resulting gross margin was 4.8% for the three months ended September 30, 2020, compared to 12.3% for the three months ended September 30, 2019. Lower gross margin for the three months ended September 30, 2020 was the result of maintaining our labor force during the uncertainty of the COVID-19 pandemic. The Company was able to secure a loan through the CARES Act Payroll Protection Program to support our workforce.

General and administrative expenses for the three months ended September 30, 2020 were $0.7 million, a decrease of $0.3 million, or 27%, compared to $1.0 million for the three months ended September 30, 2019. G&A expense decreased primarily due to tighter internal controls implemented over expense management. In addition, the utilization of remote work capabilities reduced expenditures related to facility usage, compared to the three months ended September 30, 2019.

Warehousing and other operating expenses for the three months ended September 30, 2020 were $0.2 million, a decrease of $0.1 million, or 39%, compared to $0.3 million for the three months ended September 30, 2019. Warehousing and other operating expenses include Company-owned solar array depreciation and salaries associated with Company-owned solar arrays, general warehousing costs, project-related travel and performance related expenses.

Operating loss for the three months ended September 30, 2020 was $0.7 million, compared to an operating income of $0.2 million for the three months ended September 30, 2019. The decrease in operating income was the result of a lack of revenue generated from operations due to the uncertainty of the COVID-19 pandemic and the Stay at Home orders issued in the State of Vermont.

Depreciation expenses for the three months ended September 30, 2020 were $0.1 million, compared to $0.2 million for the three months ended September 30, 2019. Depreciation expenses were stable when compared to the three months ended September 30, 2019 as the Company has not had significant capital expenditures for the three months ended September 30, 2020.

Income tax benefit for the three months ended September 30, 2020 was $0.2 million compared to the income tax provision for the three months ended September 30, 2019 of $0.5 million.

Net loss for the three months ended September 30, 2020 was $0.5 million, compared to a net income of $0.8 million for the there months ended September 30, 2019. The net loss was the result of a lack of revenue generated from operations due to the uncertainty of the COVID-19 pandemic and the State of Emergency declared by the State of Vermont. The resulting earnings per share (EPS) for the three months ended September 30, 2020 was a loss of ($0.13) per diluted share, compared to a profit of $0.01 for the three months ended September 30, 2019.

Adjusted EBITDA for the three months ended September 30, 2020 was a loss of $0.5 million, compared to income of $0.4 million for the three months ended September 30, 2019.

Adjusted EPS for the three months ended September 30, 2020 was a loss of ($0.10), compared to a profit of $0.08 for the three months ended September 30, 2019.

Financial Results for the Nine Months Ended September 30, 2020

Revenue for the nine months ended September 30, 2020 was $11.7 million, a decrease of $10.2 million, or 46%, compared to $21.9 million for the nine months ended September 30, 2019.

Gross profit for the nine months ended September 30, 2020 was $0.6 million, a decrease of $3.4 million, or 86%, compared to $4.0 million for the nine months ended September 30, 2019. The resulting gross margin was 4.8% for the six months ended September 30, 2020, compared to 18.4% for the nine months ended September 30, 2019.

General and administrative expenses for the nine months ended September 30, 2020 were $2.2 million, an increase of $0.2 million, or 11%, compared to $2.0 million for the nine months ended September 30, 2019.

Warehousing and other operating expenses for the nine months ended September 30, 2020 were $0.6 million, a decrease of $0.4 million, or 46%, compared to $1.0 million for the nine months ended September 30, 2019.

Operating loss for the nine months ended September 30, 2020 was $2.2 million, compared to an operating income of $1.0 million for the nine months ended September 30, 2019.

Depreciation expenses for the nine months ended September 30, 2020 were $0.4 million, compared to $0.5 million for the nine months ended September 30, 2019.

Income tax benefit for the nine months ended September 30, 2020 was $0.6 million compared to the income tax provision for the nine months ended September 30, 2019 of $1.6 million.

Net loss for the nine months ended September 30, 2020 was $1.8 million, compared to a net loss of $0.7 million for the nine months ended September 30, 2019. The resulting earnings per share (EPS) for the nine months ended September 30, 2020 was a loss of ($0.37) per diluted share, compared to a loss of ($0.17) for the nine months ended September 30, 2019.

Adjusted EBITDA for the nine months ended September 30, 2020 was a loss of $1.7 million, compared to income of $1.7 million for the nine months ended September 30, 2019.

Adjusted EPS for the nine months ended September 30, 2020 was a loss of ($0.33), compared to a profit of $0.42 for the nine months ended September 30, 2019.

The reconciliations of EBITDA, Adjusted EBITDA to net (loss) income, the most directly comparable financial measure calculated and presented in accordance with GAAP, are shown in the table below:

		Three months ended September 30,								Nine months ended September 30,
		2020				2019				2020				2019
Net income (loss)		$	(515,680	)		$	76,155			$	(1,777,342	)		$	(697,909	)
Depreciation and amortization			138,164				155,169				448,188				466,222
Other expense, net			72,554				54,671				218,730				158,217
Income Tax			(209,000)				48,468				(630,585	)			1,555,330
EBITDA			(513,962	)			334,463				(1,741,009	)			1,481,860
Other costs			–				78,388				–				243,819
Adjusted EBITDA			(513,962	)			412,851				(1,741,009	)			1,725,679
Weighted Average shares outstanding			5,298,159				5,474,695				5,298,159				4,071,497
Adjusted Earnings per share			(0.10	)			0.08				(0.33	)			0.42

Certain Non-GAAP Measures

We periodically review the following key non-GAAP measures to evaluate our business and trends, measure our performance, prepare financial projections and make strategic decisions.

EBITDA, Adjusted EBITDA and Earnout Adjusted EBITDA

Included in this presentation are discussions and reconciliations of earnings before interest, income tax and depreciation and amortization (“EBITDA”) and EBITDA adjusted for certain non-cash, non-recurring or non-core expenses (“Adjusted EBITDA”) to net income in accordance with GAAP. Adjusted EBITDA excludes certain non-cash and other expenses, certain legal services costs, professional and consulting fees and expenses, and one-time business combination expenses and certain adjustments. We believe that these non-GAAP measures illustrate the underlying financial and business trends relating to our results of operations and comparability between current and prior periods. We also use these non-GAAP measures to establish and monitor operational goals.

These non-GAAP measures are not in accordance with, or an alternative to, GAAP and should be considered in addition to, and not as a substitute or superior to, the other measures of financial performance prepared in accordance with GAAP. Using only the non-GAAP financial measures, particularly Adjusted EBITDA, to analyze our performance would have material limitations because such calculations are based on a subjective determination regarding the nature and classification of events and circumstances that investors may find significant. We compensate for these limitations by presenting both the GAAP and non-GAAP measures of our operating results. Although other companies may report measures entitled “Adjusted EBITDA” or similar in nature, numerous methods may exist for calculating a company’s Adjusted EBITDA or similar measures. As a result, the methods that we use to calculate Adjusted EBITDA may differ from the methods used by other companies to calculate their non-GAAP measures.

About The Peck Company Holdings, Inc.

Headquartered in South Burlington, VT, The Peck Company Holdings, Inc. is a 2nd-generation family business founded in 1972 and rooted in values that align people, purpose, and profitability. Ranked by Solar Power World as one of the leading commercial solar contractors in the Northeastern United States, the Company provides EPC services to solar energy customers for projects ranging in size from several kilowatts for residential properties to multi-megawatt systems for large commercial and utility scale projects. The Company has installed over 125 megawatts worth of solar systems since it started installing solar in 2012 and continues its focus on profitable growth opportunities. Please visit www.peckcompany.com for additional information.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as “may,” “should,” “expects,” “could,” “intends,” “plans,” “anticipates,” “estimates,” “believes,” “forecasts,” “predicts” or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, effective tax rate, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.

The forward-looking statements included in this press release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the risk factors described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

All forward-looking statements included in this press release are based on information currently available to us, and we assume no obligation to update any forward-looking statement except as may be required by law.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction with Sunworks or otherwise. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, and no offer to sell or solicitation of an offer to buy shall be made in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additional Information and Where to Find It

In connection with the proposed transaction with Sunworks, on October 1, 2020, we filed with the SEC a registration statement on Form S-4 (Registration No. 333-249183) (the “Registration Statement”), which included a document that serves as a prospectus of Peck and a joint proxy statement of Sunworks and Peck (the “Joint Proxy Statement”). These materials have not yet been declared effective, are not yet final and may be amended. After the Registration Statement has been declared effective by the SEC, the Joint Proxy Statement will be delivered to stockholders of Sunworks and Peck. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SECURITY HOLDERS OF SUNWORKS AND PECK ARE URGED TO READ THE REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE PROPOSED TRANSACTION FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Free copies of the Joint Proxy Statement, as well as other filings containing information about Peck and Sunworks, may be obtained at the SEC’s website, www.sec.gov, when they are filed. Stockholders and investors will also be able to obtain these documents, when they are filed, free of charge, by directing a request to The Peck Company Holdings, Inc., 4050 Williston Road, #511 South Burlington, Vermont 05403, Attention: Corporate Secretary, or by calling (802) 658-3378, or to Sunworks, Inc., 1030 Winding Creek Road, Suite 100, Roseville CA 95678, Attention: Corporate Secretary, or by calling (916) 409-6900, or by accessing Peck’s website at www.peckcompany.com under the “Company – Investors” tab or by accessing the Sunworks’ website at www.sunworksusa.com under the “Investor Relations” tab.

Participants in the Solicitation

Peck, and its respective directors, and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Peck in connection with the proposed transaction. Information about Peck’s directors and executive officers is available in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on April 14, 2020. Information regarding all of the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the Joint Proxy Statement regarding the proposed transaction and other relevant materials to be filed with the SEC when they become available. Free copies of these documents may be obtained as described in the preceding paragraph.

The Peck Company Holdings, Inc. Condensed Consolidated Balance Sheets (Unaudited) September 30, 2020 and December 31, 2019
		September 30, 2020				December 31, 2019
Assets
Current Assets:
Cash		$	118,450			$	95,930
Accounts receivable, net of allowance			9,998,463				7,294,605
Costs and estimated earnings in excess of billings			1,241,667				1,272,372
Other current assets			147,431				201,326
Total current assets			11,506,011				8,864,233
Property and equipment:
Building and improvements			672,727				672,727
Vehicles			1,283,364				1,283,364
Tools and equipment			517,602				517,602
Solar arrays			6,386,025				6,386,025
			8,859,718				8,859,718
Less accumulated depreciation			(2,641,196	)			(2,193,007	)
			6,218,522				6,666,711
Other Assets:
Investment in GreenSeed Investors, LLC			4,824,444				–
Investment in Solar Project Partners, LLC			96,052				–
Captive insurance investment			198,105				140,875
Total assets		$	22,843,134			$	15,671,819
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable, includes bank overdrafts of $524,324 and $1,496,695 at September 30, 2020 and December 31, 2019, respectively		$	3,245,792			$	4,274,517
Accrued expenses			74,674				119,211
Billings in excess of costs and estimated earnings on uncompleted contracts			3,301,903				126,026
Due to stockholders			37,315				342,718
Line of credit			4,907,521				3,185,041
Current portion of deferred compensation			27,880				27,880
Current portion of long-term debt			352,814				426,254
Total current liabilities			11,947,899				8,501,647
Long-term liabilities:
Deferred compensation, net of current portion			65,633				88,883
Deferred tax liability			467,146				1,098,481
Long-term debt, net of current portion			3,202,541				1,966,047
Total liabilities			15,683,219				11,655,058
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Preferred stock – 0.0001 par value 1,000,000 shares authorized, 200,000 and 0 issued and outstanding at September 30, 2020 and December 31, 2019, respectively (Liquidation Value of $5,000,000)			20				–
Common stock – 0.0001 par value 49,000,000 shares authorized, 5,298,159 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively			529				529
Additional paid-in capital-common stock			5,508,388				412,356
Retained earnings			1,650,978				3,603,876
Total Stockholders’ equity			7,159,915				4,016,761
Total liabilities and stockholders’ equity		$	22,843,134			$	15,671,819

The Peck Company Holdings, Inc. Condensed Consolidated Statements of Operations (Unaudited) For the three and nine months ended September 30, 2020 and 2019
		Three Months ended September 30,								Nine Months ended September 30,
		2020				2019				2020				2019
Earned revenue		$	4,966,026			$	11,749,580			$	11,720,932			$	21,878,170
Cost of earned revenue			4,728,328				10,308,936				11,162,439				17,846,681
Gross profit			237,698				1,440,644				558,493				4,031,489
Warehousing and other operating expenses			180,471				294,154				556,927				1,034,965
General and administrative expenses			709,353				967,196				2,190,763				1,980,886
Total operating expenses			889,824				1,261,350				2,747,690				3,015,851
Operating income			(652,126	)			179,294				(2,189,197	)			1,015,638
Other expenses
Interest expense			(72,554	)			(54,671	)			(218,730	)			(158,217	)
(Loss) income before income taxes			(724,680	)			124,623				(2,407,927	)			857,421
(Benefit) provision for income taxes			(209,000	)			48,468				(630,585	)			1,555,330
Net (loss) income			(515,680	)			76,155				(1,777,342	)			(697,909	)
Net income applicable to preferred shareholders			(175,556	)			–				(175,556	)			–
Net (loss) income available to share of common stockholders		$	(691,236	)		$	76,155			$	(1,952,898	)		$	(697,909	)
Net (loss) income available to common stockholder:
Weighted average shares of common stock outstanding
Basic and diluted			5,298,159				5,474,695				5,298,159				4,071,497
Basic and diluted		$	(0.13	)		$	0.01			$	(0.37	)		$	(0.17	)

The Peck Company Holdings, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended September 30, 2020 and 2019
		2020				2019
Cash flows from operating activities
Net loss		$	(1,777,342	)		$	(697,909	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			448,189				466,222
Deferred finance charge amortization			3,277				–
Bad debt expense			164,292				–
Deferred tax (benefit) provision			(631,335	)			1,527,311
Changes in operating assets and liabilities:
Accounts receivable			(2,868,150	)			(5,103,347	)
Other current assets			53,895				(210,852	)
Costs and estimated earnings in excess of billings			30,705				(2,709,006	)
Accounts payable			(1,028,725	)			2,085,197
Accrued expenses			(44,537	)			43,425
Billings in excess of costs and estimated earnings on uncompleted contracts			3,175,877				645,385
Deferred compensation			(23,250	)			(20,165	)
Net cash used in operating activities			(2,497,104	)			(3,973,739	)
Cash flows from investing activities:
Purchase of solar arrays and equipment			–				(39,243	)
Investment costs			–				(129,100	)
Cash surrender value of life insurance			–				(54,689	)
Investment in captive insurance			(57,230	)			(60,063	)
Net cash used in investing activities			(57,230	)			(283,095	)
Cash flows from financing activities:
Net borrowings on line of credit			2,232,580				4,027,476
Payments of line of credit			(510,100	)			–
Proceeds from long-term debt			1,487,624				–
Payments of long-term debt			(327,847	)			(230,629	)
Payments to stockholders			(305,403	)			–
Due to stockholders			–				395,070
Stockholder distributions paid			–				(219,600	)
Net cash provided by financing activities			2,576,854				3,972,317
Net increase (decrease) in cash			22,520				(284,517	)
Cash, beginning of period			95,930				313,217
Cash, end of period		$	118,450			$	28,700
Supplemental disclosure of cash flow information
Cash paid during the year for:
Interest		$	215,453			$	158,217
Income taxes			366				5,859
Supplemental schedule of non-cash investing and financing activities:
Shares of Preferred Stock issued for investment		$	5,000,000			$	–
Warrants issued for investment		$	96,052			$	–
Preferred dividends satisfied with distribution from investment		$	175,556
Vehicle purchased and financed		$	–			$	127,161
Accrued S corporation distributions which have not been paid		$	–			$	266,814

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005348/en/

Michael d’Amato

[email protected]

p802-264-2040

ClearThink

[email protected]

KEYWORDS: Vermont United States North America

INDUSTRY KEYWORDS: Alternative Energy Energy Environment Other Energy Utilities

MEDIA:

Posted on November 12, 2020 8:33 am

NutraLife BioSciences, Inc. (NLBS) Provides Company Update

Coconut Creek, FL, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) (OTC: NLBS) today provided the following shareholder update regarding NutraLife’s journey this past year and the outlook moving forward.

It’s been quite the year, and it’s hard to believe that 2020 is almost over. This year has been the most challenging for many of us. We have all had to face the trials and tribulations brought on by the COVID-19 pandemic, our political elections, and the unrest we face together as a country and global society.

As we continue to press on, we have had to adapt and adjust our operations to accommodate the current environment and meet the challenges presented head-on.  

Upon entering the new year and in the wake of the global pandemic, the Company regrouped and took the necessary steps to secure the Company’s future and survive the economic slowdown. We began by making a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and demand for sanitizer products. To do so, consistent with Food and Drug Administration (FDA) requirements, the Company registered and obtained a labeler code as an over-the-counter (OTC) manufacturing facility and began manufacturing and distributing a line of liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands,” packaged as a multi-use sanitizer spray, formulated per the CDC’s recommendation of containing at least 60-95% ethanol or isopropanol alcohol to be effective. Recently, NutraLife announced it had secured distribution of the Company’s sanitizer sprays with W.W. Grainger Inc., a New York Stock Exchange (NYSE) listed national distributor. 

This month, the Company announced that it had signed a multi-year production, fulfillment, and distribution agreement with 27Health Inc. to launch its patent-pending Oral Sanitizer mouth spray which we hope will provide some protection from viruses by reducing viral transmission. We are excited about the new product launch and the possibility of another revenue-producing line of products that the Company will be manufacturing and distributing.

Closing out the year and moving forward, the Company is focusing its efforts on getting the Company’s SEC filings current while continuing to drive sales revenue. Over the years, the Company has developed and acquired many products, including the Company’s patented derma-bug-patch insect repellent, a line of CBD products, and now a line of sanitizer products, with several other health and wellness products in development that the Company will manufacture and distribute. The Company also plans to establish a medical advisory board and research department to begin efficacy studies on the Company’s various lines of products. 

“We are pleased to be continuing on the path we set out on over 10 years ago, with the vision of becoming a leader in the nutraceutical space, creating and providing result-driven products that deliver daily health and wellness benefits to help improve the quality of life for people and their pets,” said Edgar Ward, NutraLife’s Founder/President and CEO. “While the days ahead will continue to have challenges to overcome, we will meet them head-on. To our customers and shareholders, we are grateful for your support, and thank you all!”

About the Company

NutraLife BioSciences, Inc. operates a multifaceted life sciences company. For more than seven years, NutraLife has manufactured and distributed private label and branded nutraceutical and skincare wellness products. 

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions.  The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on April 2, 2019, as amended. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

Posted on November 12, 2020 8:33 am

Coro Global Inc. to Present at Upcoming Conferences

Coro Global Inc. to Present at Upcoming Conferences

MIAMI–(BUSINESS WIRE)–
Coro Global Inc. (OTCQB: CGLO), a fintech company creating a new payment system where gold can be used in everyday transactions as easily as fiat currencies, today announced that the Company will present at the following virtual investor conferences:

• On Wednesday, November 18, 2020 the Company will present at The Fall Investor Summit. The presentation will begin at 10:30 AM ET.

• On Thursday, November 19, 2020 the Company will present at Sidoti’s Virtual Microcap Conference. The presentation will begin at 11:30 AM ET.

Investors and interested parties can access the presentations by visiting the Company’s investor relations website at https://ir.coro.global.

About Coro Global Inc.

Coro Global Inc. is a Miami, Florida-based fintech company that is creating a new financial payment system where gold can be used as money in everyday transactions as easily as fiat currencies. Coro’s platform is powered by cutting-edge Distributed Ledger Technology, allowing customers to send and receive global payments and exchange currency, including gold, seamlessly and securely.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005273/en/

PR contact

Craig Corbett

Publicize

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Professional Services Mining/Minerals Technology Natural Resources Software Finance Banking

MEDIA:

Posted on November 12, 2020 8:33 am

Notice of Flow Capital’s 2020 Third Quarter Financial Results Conference Call

Financial results to be released after markets on Tuesday, November 17, 2020

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”) today announced it will release its 2020 third quarter financial results after the markets close on Tuesday, November 17, 2020. Mr. Alex Baluta, Chief Executive Officer, and Mr. Gaurav Singh, Chief Financial Officer, will host a conference call at 8:30 a.m. ET, on Wednesday, November 18, 2020, to review the results. A question and answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE:	Wednesday, November 18, 2020
TIME:	8:30 AM Eastern Time
DIAL IN NUMBER:	+1 833 968-1926 or +1 778 560-2703
TAPED REPLAY:	+1 800 585-8367 or +1 416 621-4642
CONFERENCE ID:	4878065

A recording of the call will be archived on the Company’s website at www.flowcap.com/financials/.

About FlowCapital
Flow Capital Corp. is a diversified alternative asset investor and advisor, specializing in providing minimally dilutive capital to emerging growth businesses. To apply for financing, visit www.flowcap.com.

For
further
information,
please
contact:

Flow Capital
Corp.:

Alex
Baluta

Chief
Executive
Officer
Tel: (416) 777-0383

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.